AbbVie's migraine drug clears late-stage trial for menstrual migraine prevention
AbbVie announced that its migraine treatment met the main goal of a late-stage study testing it as a preventive therapy for menstrual migraine in adults.
AbbVie said its migraine treatment met the primary objective of a late-stage clinical trial evaluating the therapy as a preventive option for menstrual migraine in adults.
The announcement, made on Thursday, marks a key milestone for the drug in an indication that affects a significant number of women. Menstrual migraine is a distinct subtype of migraine that occurs in association with the menstrual cycle, often proving difficult to manage with standard treatments.
The study was designed to assess the treatment's ability to prevent migraine attacks linked to menstruation. By meeting its main goal, the trial provides evidence that the therapy could offer a new preventive approach for patients in this category.
AbbVie did not disclose additional details from the trial in the initial announcement. Further data from the study are expected to be presented or published in due course, which will allow for a fuller assessment of the treatment's efficacy and safety profile in this specific population.
The result adds to the company's efforts in the migraine space, where preventive therapies have become an area of growing research focus. Regulatory next steps have not yet been outlined.